STARHEALTH - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 3.7
| Stock Code | STARHEALTH | Market Cap | 27,137 Cr. | Current Price | 461 ₹ | High / Low | 534 ₹ |
| Stock P/E | 60.8 | Book Value | 127 ₹ | Dividend Yield | 0.00 % | ROCE | 12.0 % |
| ROE | 9.37 % | Face Value | 10.0 ₹ | DMA 50 | 461 ₹ | DMA 200 | 460 ₹ |
| Chg in FII Hold | 0.56 % | Chg in DII Hold | -0.13 % | PAT Qtr | 128 Cr. | PAT Prev Qtr | 54.9 Cr. |
| RSI | 51.2 | MACD | -0.74 | Volume | 4,94,550 | Avg Vol 1Wk | 5,28,859 |
| Low price | 327 ₹ | High price | 534 ₹ | PEG Ratio | 1.62 | Debt to equity | 0.06 |
| 52w Index | 64.7 % | Qtr Profit Var | -40.4 % | EPS | 7.59 ₹ | Industry PE | 33.4 |
📊 Analysis: STARHEALTH is trading at ₹461, exactly at its 50 DMA (₹461) and 200 DMA (₹460), showing neutral technical positioning. RSI at 51.2 indicates balanced momentum, while MACD (-0.74) reflects mild bearishness. Current volume (4.9 lakh) is slightly below the 1-week average (5.2 lakh), suggesting moderate intraday participation. Fundamentals show high valuation with weak efficiency, though recent profit improvement provides some support.
💡 Optimal Buy Price: Around ₹455–462 if support holds near ₹455.
🎯 Profit Exit Levels: ₹470–475 (first resistance), ₹485 (secondary resistance).
🛡️ Stop-Loss: ₹448 (below intraday support).
⏱️ If Already Holding: Consider exiting near ₹470–475 if momentum stalls. If price fails to sustain above ₹455 with weak volume, exit early to protect gains.
✅ Positive
- Quarterly PAT improved to ₹128 Cr from ₹54.9 Cr.
- FII holdings increased by 0.56%, showing foreign investor confidence.
- 52-week performance shows 64.7% gain, reflecting strong investor sentiment.
- PEG ratio at 1.62 suggests fair valuation relative to growth.
⚠️ Limitation
- High P/E of 60.8 compared to industry average of 33.4.
- ROCE at 12.0% and ROE at 9.37% are modest.
- Dividend yield at 0.00%, offering no income support.
- Volume slightly below average, limiting intraday momentum.
📉 Company Negative News
- Quarterly profit variance at -40.4% shows earnings pressure despite improvement.
- DII holdings decreased by 0.13%, showing reduced domestic support.
- MACD remains negative, indicating weak short-term momentum.
📈 Company Positive News
- Quarterly PAT growth shows earnings recovery.
- FII inflows reflect foreign confidence.
- Stock trading at DMA levels, offering potential breakout opportunity.
🏭 Industry
- Industry PE at 33.4, much lower than STARHEALTH’s 60.8, suggesting sector peers are more attractively valued.
- Health insurance sector remains in growth phase, supported by rising demand and regulatory push for coverage expansion.
🔎 Conclusion
STARHEALTH shows neutral technical positioning with improving profits and foreign investor confidence. However, high valuation, modest efficiency, and weak momentum limit upside. Suitable for cautious intraday trades with tight stop-losses and profit booking near resistance levels.
Would you like me to extend this into a basket overlay scan with peers like ICICI Lombard, HDFC Life, and SBI Life to benchmark STARHEALTH’s intraday strength against the broader insurance sector?